Rejuvenation in older adults receiving oral ghrelin.

摘要

TO THE EDITOR: I read with interest the study by Nass and colleagues (1). I would like to address some critical issues, with particular reference to adverse events. First, growing evidence suggests that IGF-I is a cytokine involved in promotion and induction of oncogenesis in different types of tumors, such as Ewing sarcoma (2), renal cell carcinoma (3), and adenocarcinoma of the gastrointestinal tract (for example, colorectal carcinoma [4] and cholangiocellular carcinoma). Why didn't the authors report the results of screening methods (fecal occult blood test, abdominal ultrasonography, colonoscopy) or staging of reported adverse events?